Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecule drugs targeting cancer and gastrointestinal diseases.
Under the agreeme
Continue Reading on The Star Malaysia
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.